Big Bristol-Myers Shareholder Opposes Celgene Deal

One of Bristol-Myers’s largest shareholders is opposing the company’s $74 billion deal to buy rival Celgene, becoming the latest investor to express its unhappiness with the transaction.

from WSJ.com: US Business https://ift.tt/2Vp3T2t
via IFTTT